- NCIt
- C7185
Loading cancer entity…
Loading cancer entity…
Clinical trials
900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (130)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06859008 | Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 37 | City of Hope Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07535710 | Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 37 | Shanghai Jiao Tong University School of MedicineOTHER | 1 |
| Apr 17, 2026 |
| clinicaltrials |
| NCT03328078 | CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) | recruiting | Phase 1 / Phase 2 | 152 | Curis, Inc.INDUSTRY | 7 | Apr 16, 2026 | clinicaltrials |
| NCT03398161 | Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides | recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03680586 | Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma | active not recruiting | Early Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03684980 | LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma | active not recruiting | Early Phase 1 | 58 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07356245 | Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma | recruiting | Phase 2 | 44 | Jonathan BrammerOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07523737 | Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma | recruiting | Phase 2 | 43 | Beijing Tongren HospitalOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06544265 | SynKIR-310 for Relapsed/Refractory B-NHL | recruiting | Phase 1 | 36 | Verismo TherapeuticsINDUSTRY | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07529405 | A Study of VG712 in Patients With Mycosis Fungoides(CurbMF) | not yet recruiting | Phase 2 | 386 | Virogen Biotechnology Inc.INDUSTRY | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07525466 | Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH) | recruiting | Phase 1 / Phase 2 | 25 | Beijing Tongren HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04911478 | Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells | active not recruiting | — | 50 | Adicet TherapeuticsINDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT03697512 | MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas(MALIBU) | active not recruiting | Phase 2 | 175 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 5 | Apr 8, 2026 | clinicaltrials |
| NCT03240211 | Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL | active not recruiting | Phase 1 | 37 | University of VirginiaOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT04417166 | Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma | active not recruiting | Phase 2 | 30 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT03587844 | Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients | recruiting | Phase 2 | 58 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06208735 | CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies | recruiting | Phase 1 | 24 | British Columbia Cancer AgencyOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07047885 | Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL) | recruiting | Phase 1 | 38 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04947319 | Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) | active not recruiting | Phase 2 | 119 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04830137 | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | recruiting | Phase 1 | 248 | Nurix Therapeutics, Inc.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT02952508 | Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom(CLOVER-WaM) | active not recruiting | Phase 2 | 120 | Cellectar Biosciences, Inc.INDUSTRY | 11 | Mar 18, 2026 | clinicaltrials |
| NCT04931368 | OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma(OptiMATe) | active not recruiting | Phase 3 | 331 | Klinikum StuttgartOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06026319 | CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma | recruiting | Phase 1 | 24 | Marcela V. Maus, M.D.,Ph.D.OTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07473167 | Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients(TC011) | recruiting | Phase 1 / Phase 2 | 98 | TICAROS Co., Ltd.INDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07463781 | Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy(NEURO_CAR-T) | not yet recruiting | — | 100 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05256641 | Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 24 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07457177 | Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL | not yet recruiting | Phase 2 | 40 | LIANG WANGOTHER | 0 | Mar 9, 2026 | clinicaltrials |
| NCT05934448 | Pembro Plus CAR T-cell Therapy in R/R in PMBCL | recruiting | Phase 2 | 35 | Jennifer Crombie, MDOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05681195 | Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas | recruiting | Phase 2 | 15 | Baptist Health South FloridaOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04186520 | CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies | recruiting | Phase 1 / Phase 2 | 100 | Medical College of WisconsinOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04421560 | Pembrolizumab, Ibrutinib and Rituximab in PCNSL | recruiting | Phase 1 / Phase 2 | 37 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT06475235 | Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL | recruiting | Phase 1 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07416890 | Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma | recruiting | Phase 2 | 24 | Zhejiang Cancer HospitalOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT05544019 | Study of SGR-1505 in Mature B-Cell Neoplasms | recruiting | Phase 1 | 98 | Schrödinger, Inc.INDUSTRY | 8 | Feb 13, 2026 | clinicaltrials |
| NCT07410520 | PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL. | recruiting | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07405255 | Zillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma(Zillion) | not yet recruiting | Phase 2 | 19 | Ruijin HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07406230 | Methotrexate Early Toxicity Monitoring(METoxiM) | not yet recruiting | N/A | 50 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07402876 | A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma | recruiting | Phase 3 | 20 | Aldeyra Therapeutics, Inc.INDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04848064 | Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma | recruiting | Phase 1 | 12 | John ReneauOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT03749018 | Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma | active not recruiting | Phase 2 | 30 | David Bond, MDOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT06485219 | A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma | active not recruiting | Phase 2 | 50 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05296304 | A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides | recruiting | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07385989 | Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma | not yet recruiting | Phase 2 | 40 | WEI XUOTHER | 0 | Feb 4, 2026 | clinicaltrials |
| NCT05633615 | Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | recruiting | Phase 2 | 396 | SWOG Cancer Research NetworkNETWORK | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04745559 | Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy | active not recruiting | Phase 2 | 26 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05583149 | Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas | active not recruiting | Phase 2 | 28 | Patrick C. Johnson, MDOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT01199562 | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | active not recruiting | — | 153 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04670874 | Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29 | recruiting | — | 1,250 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06834373 | Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy | recruiting | Phase 2 | 41 | Mayo ClinicOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06069830 | PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma(ENKTL) | recruiting | N/A | 89 | Ruijin HospitalOTHER | 1 | Jan 27, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 20, 2026source: clinicaltrials